Literature DB >> 32423903

Thrombotic risk in COVID-19: a case series and case-control study.

Simon M Stoneham1, Kate M Milne2, Elisabeth Nuttall3, Georgina H Frew3, Beattie Rh Sturrock4, Helena Sivaloganathan5, Eleni E Ladikou5, Stephen Drage3, Barbara Phillips5, Timothy Jt Chevassut6, Alice C Eziefula5.   

Abstract

BACKGROUND: A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous thromboembolism (VTE) are extremely limited.
METHODS: We describe three cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an inpatient cohort, and a case-control study to identify risk factors associated with VTE.
RESULTS: We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were seen in confirmed VTE cases (4.1 vs 1.2 μg/mL, p<0.001).
CONCLUSION: Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be beneficial in guiding management. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  COVID-19; D-dimer; deep vein thrombosis; pulmonary embolism; venous thromboembolism

Mesh：

Substances：

Year:  2020        PMID： 32423903      PMCID： PMC7385762          DOI： 10.7861/clinmed.2020-0228

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  23 in total

1.  Pandemic H1N1 influenza infection and vascular thrombosis.

Authors:  Paul E Bunce; Sasha M High; Maral Nadjafi; Katherine Stanley; W Conrad Liles; Michael D Christian
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 2.  Anticoagulant therapy in acute respiratory distress syndrome.

Authors:  Marta Camprubí-Rimblas; Neus Tantinyà; Josep Bringué; Raquel Guillamat-Prats; Antonio Artigas
Journal:  Ann Transl Med       Date:  2018-01

Review 3.  Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation.

Authors:  Frantzeska Frantzeskaki; Apostolos Armaganidis; Stylianos E Orfanos
Journal:  Respiration       Date:  2016-12-21       Impact factor: 3.580

4.  Causes of elevated D-dimer in patients admitted to a large urban emergency department.

Authors:  Giuseppe Lippi; Laura Bonfanti; Carlotta Saccenti; Gianfranco Cervellin
Journal:  Eur J Intern Med       Date:  2013-08-13       Impact factor: 4.487

Review 5.  Antithrombin III for critically ill patients.

Authors:  Mikkel Allingstrup; Jørn Wetterslev; Frederikke B Ravn; Ann Merete Møller; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-02-08

6.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors:  Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal:  Science       Date:  2020-03-04       Impact factor: 47.728

7.  D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Thromb Haemost       Date:  2020-04-03       Impact factor: 5.249

8.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

Authors:  Tao Chen; Di Wu; Huilong Chen; Weiming Yan; Danlei Yang; Guang Chen; Ke Ma; Dong Xu; Haijing Yu; Hongwu Wang; Tao Wang; Wei Guo; Jia Chen; Chen Ding; Xiaoping Zhang; Jiaquan Huang; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  BMJ       Date:  2020-03-26

9.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

10.  Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Clin Chim Acta       Date:  2020-03-04       Impact factor: 3.786
View more
  35 in total

1.  Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies.

Authors:  Gaurav Agarwal; Adrija Hajra; Sandipan Chakraborty; Neelkumar Patel; Suman Biswas; Mark K Adler; Carl J Lavie
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

2.  Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.

Authors:  Carina Conzelmann; Janis A Müller; Lukas Perkhofer; Konstantin Mj Sparrer; Alexander N Zelikin; Jan Münch; Alexander Kleger
Journal:  Clin Med (Lond)       Date:  2020-08-30       Impact factor: 2.659

3.  Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?

Authors:  Eleni E Ladikou; Helena Sivaloganathan; Kate M Milne; William E Arter; Roshan Ramasamy; Ramy Saad; Simon M Stoneham; Barbara Philips; Alice C Eziefula; Timothy Chevassut
Journal:  Clin Med (Lond)       Date:  2020-07-21       Impact factor: 2.659

Review 4.  Imaging of COVID-19: An update of current evidences.

Authors:  Shingo Kato; Yoshinobu Ishiwata; Ryo Aoki; Tae Iwasawa; Eri Hagiwara; Takashi Ogura; Daisuke Utsunomiya
Journal:  Diagn Interv Imaging       Date:  2021-05-25       Impact factor: 7.242

5.  Impact of affluence on the local spread of SARS-CoV2 during the first wave of the COVID-19 pandemic.

Authors:  B R H Sturrock; E I Chevassut; A Shahvisi; T J T Chevassut
Journal:  Public Health Pract (Oxf)       Date:  2021-05-19

Review 6.  Thromboembolic Complications of SARS-CoV-2 and Metabolic Derangements: Suggestions from Clinical Practice Evidence to Causative Agents.

Authors:  Francesco Nappi; Adelaide Iervolino; Sanjeet Singh Avtaar Singh
Journal:  Metabolites       Date:  2021-05-25

Review 7.  A review of thromboembolic events in hospitalized COVID-19 patients.

Authors:  Paul Fontelo; Mrigendra M Bastola; Zhaonian Zheng; Seo Hyon Baik
Journal:  Thromb J       Date:  2021-06-29

Review 8.  Heterogeneity in reporting venous thromboembolic phenotypes in COVID-19: methodological issues and clinical implications.

Authors:  Anastasios Kollias; Konstantinos G Kyriakoulis; George S Stergiou; Konstantinos Syrigos
Journal:  Br J Haematol       Date:  2020-07-26       Impact factor: 8.615

9.  COVID-19 mortality in patients on anticoagulants and antiplatelet agents.

Authors:  Helena Sivaloganathan; Eleni E Ladikou; Timothy Chevassut
Journal:  Br J Haematol       Date:  2020-07-19       Impact factor: 8.615

Review 10.  Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.

Authors:  Sakir Ahmed; Olena Zimba; Armen Yuri Gasparyan
Journal:  Clin Rheumatol       Date:  2020-07-11       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.